Drug Profile
Research programme: GPBAR1 protein agonist - SatRx
Latest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator SatRx
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in Russia (unspecified route)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Russia
- 27 Sep 2016 Preclinical trials in Type-2 diabetes mellitus in Russia (unspecified route) prior to September 2016 (SatRx pipeline, September 2016)